The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620836
Title:
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Authors:
Mullish, B. H. [et al]; Baxter, Melissa; Colville, Alaric
Abstract:
Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.
Citation:
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. 2018 67(11):1920-1941 Gut
Publisher:
BMJ
Journal:
Gut
Issue Date:
28-Aug-2018
URI:
http://hdl.handle.net/11287/620836
DOI:
10.1136/gutjnl-2018-316818
PubMed ID:
30154172
Additional Links:
http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=30154172
Type:
Journal Article
Language:
en
ISSN:
1468-3288
Appears in Collections:
Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology); 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMullish, B. H. [et al]en
dc.contributor.authorBaxter, Melissaen
dc.contributor.authorColville, Alaricen
dc.date.accessioned2018-10-02T13:40:06Z-
dc.date.available2018-10-02T13:40:06Z-
dc.date.issued2018-08-28-
dc.identifier.citationThe use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. 2018 67(11):1920-1941 Guten
dc.identifier.issn1468-3288-
dc.identifier.pmid30154172-
dc.identifier.doi10.1136/gutjnl-2018-316818-
dc.identifier.urihttp://hdl.handle.net/11287/620836-
dc.description.abstractInterest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.en
dc.language.isoenen
dc.publisherBMJen
dc.relation.urlhttp://gut.bmj.com/cgi/pmidlookup?view=long&pmid=30154172en
dc.rightsArchived with thanks to Guten
dc.subjectWessex Classification Subject Headings::Microbiology. Immunologyen
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleThe use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.en
dc.typeJournal Articleen
dc.identifier.journalGuten
dc.type.versionIn press (epub ahead of print)en
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.